Bridging Tradition and Forward-Thinking Solutions to Shape the Future of Healthcare

Pangea Pharmaceuticals, a dynamic and forward-thinking pharmaceutical company, is reshaping the healthcare landscape with its innovative approach to drug development, distribution, and patient access. Founded in 2018 by industry veterans Anthony LaViola (CEO) and Steve Flood (President), Pangea Pharmaceuticals combines cutting-edge pharmaceutical solutions with a commitment to accessibility, quality, and integrity. The company is setting new standards in healthcare, with a growing product portfolio and an expanding presence in key therapeutic areas.

“We believe success in pharma doesn’t come from playing it safe. At Pangea, we don’t play it safe; we anticipate trends and create them, setting new standards across the industry,” said Tony LaViola, CEO and Co-Founder of Pangea Pharmaceuticals.

About Pangea Pharmaceuticals
Pangea Pharmaceuticals is a leader in healthcare solutions, committed to making life-enhancing medications accessible to patients worldwide. Our mission is to bridge innovation and tradition by delivering life-changing healthcare options that make a real difference in patients’ lives. With a focus on niche brand and generic products, Pangea is committed to improving healthcare access for those in need, without compromising on quality. Our core values—Innovation, Accessibility, Integrity, Commitment, and Quality—drive every aspect of our work. We challenge norms to create impactful, patient-centric treatments while maintaining the highest ethical standards. By focusing on high-value product development, Pangea aims to lead the next era of pharmaceuticals, setting new benchmarks for what’s possible in healthcare.

Pangea’s Growth and Achievements
Since its founding, Pangea has rapidly expanded its pipeline and market presence. In just a few short years, the company has launched three products in 2024 and one more so far in 2025, with over 15 more scheduled to hit the market in the next two years, either under the Pangea label or licensed to commercial partners. Pangea’s lean and nimble operating model—low-cost, high-margin EBITDA—has positioned itself as a fast-growing player in the pharmaceutical industry. Pangea’s business model focuses on developing drug formulations both independently and in collaboration with trusted partners. With exclusive partnerships for Active Pharmaceutical Ingredients (APIs) and finished product manufacturing, the company is positioned to lead the way in institutional, specialty, and generic product markets.

A Commitment to Patient-Centric Innovation
Pangea Pharmaceuticals’ latest product launch illustrates the company’s commitment to meeting unmet medical needs. A significant new treatment poised to make an impact: Ergomar® Sublingual Tablets (2mg) – Released in February 2025, this FDA-approved sublingual treatment provides relief for acute migraine and cluster headaches. As the only FDA-approved sublingual treatment for vascular headaches, Ergomar® expands Pangea’s therapeutic reach into the migraine treatment market. More information available at www.ergomar.com.

A Vision for the Future
Pangea Pharmaceuticals has a bold vision: to lead the next era of pharmaceutical innovation by setting a new standard in healthcare access, where no treatment is beyond reach. With a rapidly growing portfolio, low operational costs, and a strong foundation of ethical business practices, Pangea is primed for continued success and expansion.

“We are just getting started,” said LaViola. “Pangea is not just a pharmaceutical company; it’s a movement toward better healthcare for all. Our future is bright, and we are eager to build on our momentum to make an even greater impact in the years to come.”

For more information, visit www.pangeapharm.com.

Media Contact
For press inquiries, please contact:

Rachel Osinoff
Marketing Manager
Phone: 914-438-1480
Email: rosinoff@pangeapharm.com
Website: www.pangeapharm.com

Follow Pangea Pharmaceuticals on social media:
LinkedIn | Instagram | Facebook @PangeaPharmaceuticals